-
Something wrong with this record ?
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries
L. Linde, LM. Ørnbjerg, S. Georgiadis, S. H Rasmussen, U. Lindström, J. Askling, B. Michelsen, D. Di Giuseppe, JK. Wallman, B. Gudbjornsson, TJ. Love, DC. Nordström, T. Yli-Kerttula, L. Nekvindová, J. Vencovský, F. Iannone, A. Cauli, AG. Loft, B....
Language English Country England, Great Britain
Document type Journal Article
Grant support
Novartis Pharma AG
NLK
Free Medical Journals
from 1996 to 1 year ago
Open Access Digital Library
from 1996-01-01
Medline Complete (EBSCOhost)
from 1999-01-01 to 1 year ago
- MeSH
- Immunotherapy MeSH
- Tumor Necrosis Factor Inhibitors therapeutic use MeSH
- Humans MeSH
- Arthritis, Psoriatic * drug therapy MeSH
- Registries MeSH
- Fatigue MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
OBJECTIVES: In bio-naïve patients with PsA initiating a TNF inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. METHODS: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes were defined as common predictors. RESULTS: In the pooled cohort (n = 13 369), 6-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n = 6954, n = 5275 and n = 13 369, respectively). Five common baseline predictors of remission, moderate response and 12-month drug retention were identified across all three outcomes. The odds ratios (95% CIs) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (<2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP of >10 vs ≤10 mg/l: 1.52 (1.22-1.89) and 1 mm increase in patient fatigue score: 0.99 (0.98-0.99). CONCLUSION: Baseline predictors of remission, response and adherence to TNFi therapy were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalizable from country level to disease level.
Aberdeen Centre for Arthritis and Musculoskeletal Health University of Aberdeen Aberdeen UK
Amsterdam Rheumatology and Immunology Center Amsterdam The Netherlands
Center for Rheumatology and Spine Diseases Copenhagen Center for Arthritis Research Denmark
Center for Treatment of Rheumatic and Musculoskeletal Diseases Diakonhjemmet Hospital Oslo Norway
Centre for Rheumatology Research Landspitali University Hospital Reykjavik Iceland
Clinical Epidemiology Division Department of Medicine Solna Karolinska Institutet Stockholm Sweden
DANBIO Registry Rigshospitalet Glostrup Denmark
Department for Science and Research Landspitali University Hospital Reykjavik Iceland
Department of Clinical Medicine Aarhus University Aarhus Denmark
Department of Clinical Medicine University of Copenhagen Copenhagen Denmark
Department of Medicine Solna Karolinska Institutet Stockholm Sweden
Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic
Department of Rheumatology Aarhus University Hospital Aarhus Denmark
Department of Rheumatology Ankara Yıldırım Beyazıt University Ankara City Hospital Ankara Turkey
Department of Rheumatology East Tallinn Central Hospital Tallinn Estonia
Department of Rheumatology Geneva University Hospital Geneva Switzerland
Department of Rheumatology Satakunta Central Hospital Rauma Finland
Department of Rheumatology University Medical Centre Ljubljana Ljubljana Slovenia
Departments of Medicine and Rheumatology Helsinki University Hospital Helsinki Finland
Faculty of Medicine University of Iceland Reykjavik Iceland
Faculty of Medicine University of Ljubljana Ljubljana Slovenia
Institute of Rheumatology Prague Czech Republic
Research Unit Sørlandet Hospital Kristiansand Norway
Reuma pt Sociedade Portuguesa de Reumatologia Lisbon Portugal
Rheumatology Unit DETO University of Bari Bari Italy
Serviço de Reumatologia Hospital Garcia de Orta Almada Portugal
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007018
- 003
- CZ-PrNML
- 005
- 20240423155649.0
- 007
- ta
- 008
- 240412s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/rheumatology/kead284 $2 doi
- 035 __
- $a (PubMed)37314967
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Linde, Louise $u Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Denmark $u DANBIO Registry, Rigshospitalet, Glostrup, Denmark $1 https://orcid.org/0000000308631352
- 245 10
- $a Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries / $c L. Linde, LM. Ørnbjerg, S. Georgiadis, S. H Rasmussen, U. Lindström, J. Askling, B. Michelsen, D. Di Giuseppe, JK. Wallman, B. Gudbjornsson, TJ. Love, DC. Nordström, T. Yli-Kerttula, L. Nekvindová, J. Vencovský, F. Iannone, A. Cauli, AG. Loft, B. Glintborg, K. Laas, Z. Rotar, M. Tomšič, GJ. Macfarlane, B. Möller, M. van de Sande, C. Codreanu, MJ. Nissen, M. Birlik, S. Erten, MJ. Santos, E. Vieira-Sousa, ML. Hetland, M. Østergaard
- 520 9_
- $a OBJECTIVES: In bio-naïve patients with PsA initiating a TNF inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. METHODS: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes were defined as common predictors. RESULTS: In the pooled cohort (n = 13 369), 6-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n = 6954, n = 5275 and n = 13 369, respectively). Five common baseline predictors of remission, moderate response and 12-month drug retention were identified across all three outcomes. The odds ratios (95% CIs) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (<2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP of >10 vs ≤10 mg/l: 1.52 (1.22-1.89) and 1 mm increase in patient fatigue score: 0.99 (0.98-0.99). CONCLUSION: Baseline predictors of remission, response and adherence to TNFi therapy were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalizable from country level to disease level.
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a psoriatická artritida $x farmakoterapie $7 D015535
- 650 _2
- $a inhibitory TNF $x terapeutické užití $7 D000079424
- 650 _2
- $a únava $7 D005221
- 650 _2
- $a imunoterapie $7 D007167
- 650 _2
- $a registrace $7 D012042
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ørnbjerg, Lykke M $u Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Denmark $u DANBIO Registry, Rigshospitalet, Glostrup, Denmark $1 https://orcid.org/0000000278326831
- 700 1_
- $a Georgiadis, Stylianos $u Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Denmark $u DANBIO Registry, Rigshospitalet, Glostrup, Denmark
- 700 1_
- $a H Rasmussen, Simon $u Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Denmark
- 700 1_
- $a Lindström, Ulf $u Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden $1 https://orcid.org/0000000222509348
- 700 1_
- $a Askling, Johan $u Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Michelsen, Brigitte $u Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Denmark $u Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway $u Research Unit, Sørlandet Hospital, Kristiansand, Norway
- 700 1_
- $a Di Giuseppe, Daniela $u Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000338178288
- 700 1_
- $a Wallman, Johan K $u Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden $1 https://orcid.org/0000000249152924
- 700 1_
- $a Gudbjornsson, Bjorn $u Centre for Rheumatology Research, Landspitali, University Hospital, Reykjavik, Iceland $u Faculty of Medicine, University of Iceland, Reykjavik, Iceland
- 700 1_
- $a Love, Thorvardur Jon $u Faculty of Medicine, University of Iceland, Reykjavik, Iceland $u Department for Science and Research, Landspitali University Hospital, Reykjavik, Iceland
- 700 1_
- $a Nordström, Dan C $u Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland
- 700 1_
- $a Yli-Kerttula, Timo $u Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland
- 700 1_
- $a Nekvindová, Lucie $u Institute of Rheumatology, Prague, Czech Republic $u Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000288662310 $7 xx0231716
- 700 1_
- $a Vencovský, Jiří $u Institute of Rheumatology, Prague, Czech Republic $u Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Iannone, Florenzo $u Rheumatology Unit, DETO, University of Bari, Bari, Italy $1 https://orcid.org/0000000304745344
- 700 1_
- $a Cauli, Alberto $u Rheumatology Unit, Department of Medical Sciences and Public Health, AOU and University of Cagliari, Monserrato, Italy
- 700 1_
- $a Loft, Anne Gitte $u Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark $u Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
- 700 1_
- $a Glintborg, Bente $u Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Denmark $u DANBIO Registry, Rigshospitalet, Glostrup, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 700 1_
- $a Laas, Karin $u Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia
- 700 1_
- $a Rotar, Ziga $u Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia $u Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Tomšič, Matija $u Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia $u Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Macfarlane, Gary J $u Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK $1 https://orcid.org/0000000323223314
- 700 1_
- $a Möller, Burkhard $u Department for Rheumatology and Immunology, Inselspital, University Hospital Bern, on behalf of the Swiss Clinical Quality Management for Rheumatic Diseases, SCQM, Zürich, Switzerland $1 https://orcid.org/0000000187696167
- 700 1_
- $a van de Sande, Marleen $u Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Institute for Infection & Immunity, Amsterdam, The Netherlands $u Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, The Netherlands
- 700 1_
- $a Codreanu, Catalin $u Center for Rheumatic Diseases, University of Medicine and Pharmacy, Romanian Registry of Rheumatic Diseases, Bucharest, Romania
- 700 1_
- $a Nissen, Michael J $u Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland
- 700 1_
- $a Birlik, Merih $u Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey
- 700 1_
- $a Erten, Sukran $u Department of Rheumatology, Ankara Yıldırım Beyazıt University Ankara City Hospital, Ankara, Turkey
- 700 1_
- $a Santos, Maria J $u Serviço de Reumatologia, Hospital Garcia de Orta, Almada, Portugal $u Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal $1 https://orcid.org/0000000279461365
- 700 1_
- $a Vieira-Sousa, Elsa $u Department of Rheumatology, Hospital de Santa Maria, CHULN, Instituto Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal
- 700 1_
- $a Hetland, Merete L $u Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000342296818
- 700 1_
- $a Østergaard, Mikkel $u Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/000000033690467X
- 773 0_
- $w MED00011379 $t Rheumatology $x 1462-0332 $g Roč. 63, č. 3 (2024), s. 751-764
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37314967 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155645 $b ABA008
- 999 __
- $a ok $b bmc $g 2081180 $s 1216785
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 63 $c 3 $d 751-764 $e 20240301 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
- GRA __
- $p Novartis Pharma AG
- LZP __
- $a Pubmed-20240412
